Shopping Cart
- Remove All
- Your shopping cart is currently empty
JNJ-26076713, an orally active alpha V integrin antagonist, represents a potential therapeutic candidate for the treatment of macular edema, age-related macular degeneration, and proliferative diabetic retinopathy.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $4,859 | 8-10 weeks |
Description | JNJ-26076713, an orally active alpha V integrin antagonist, represents a potential therapeutic candidate for the treatment of macular edema, age-related macular degeneration, and proliferative diabetic retinopathy. |
Alias | JNJ26076713 |
Molecular Weight | 490.64 |
Formula | C29H38N4O3 |
Cas No. | 669076-03-3 |
Relative Density. | 1.31 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.